Personalgenome
3 known investors
PGDx (Personal Genome Diagnostics) develops comprehensive genomic profiling kits and bioinformatics for precision oncology, including tissue-based and liquid biopsy assays that analyze tumor DNA to guide personalized cancer treatment. Its products are designed for laboratories and care teams to run in-house testing and support cancer research and companion diagnostic (CDx) development.
BiotechHealthtechMedical Devices
Investors Β· 3
Non-dilutive funding Β· 4 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $297.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $223K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $216.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $214.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Personalgenome do?
- PGDx (Personal Genome Diagnostics) develops comprehensive genomic profiling kits and bioinformatics for precision oncology, including tissue-based and liquid biopsy assays that analyze tumor DNA to guide personalized cancer treatment. Its products are designed for laboratories and care teams to run in-house testing and support cancer research and companion diagnostic (CDx) development.
- Who are Personalgenome's investors?
- Personalgenome's investors include 3B Future Health Fund, Windham Capital Partners, Vensana Capital.